CL2016002461A1 - Derivados macrocíclicos de pirimidina - Google Patents

Derivados macrocíclicos de pirimidina

Info

Publication number
CL2016002461A1
CL2016002461A1 CL2016002461A CL2016002461A CL2016002461A1 CL 2016002461 A1 CL2016002461 A1 CL 2016002461A1 CL 2016002461 A CL2016002461 A CL 2016002461A CL 2016002461 A CL2016002461 A CL 2016002461A CL 2016002461 A1 CL2016002461 A1 CL 2016002461A1
Authority
CL
Chile
Prior art keywords
pyrimidine
macrocyclic derivatives
macrocyclic
derivatives
pyrimidine macrocyclic
Prior art date
Application number
CL2016002461A
Other languages
English (en)
Inventor
Gaston Stanislas Marcella Diels
Bruno Schoentjes
Matthias Luc Aimé Versele
Didier Jean-Claude Berthelot
Marc Willems
Marcel Viellevoye
Werner Constant Johan Embrechts
Berthold Wroblowski
Lieven Meerpoel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2016002461A1 publication Critical patent/CL2016002461A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2016002461A 2014-04-03 2016-09-29 Derivados macrocíclicos de pirimidina CL2016002461A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14163443 2014-04-03
EP14183747 2014-09-05

Publications (1)

Publication Number Publication Date
CL2016002461A1 true CL2016002461A1 (es) 2017-06-23

Family

ID=52781117

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002461A CL2016002461A1 (es) 2014-04-03 2016-09-29 Derivados macrocíclicos de pirimidina

Country Status (21)

Country Link
US (1) US10017509B2 (es)
EP (1) EP3126364B1 (es)
JP (1) JP6529513B2 (es)
KR (1) KR102390276B1 (es)
CN (2) CN106164075B (es)
AU (1) AU2015239098B2 (es)
BR (1) BR112016021982B1 (es)
CA (1) CA2942636C (es)
CL (1) CL2016002461A1 (es)
EA (1) EA031246B1 (es)
ES (1) ES2667723T3 (es)
IL (1) IL248005B (es)
MA (1) MA39822A (es)
MX (1) MX369798B (es)
MY (1) MY185491A (es)
NZ (1) NZ725399A (es)
PE (1) PE20161362A1 (es)
PH (1) PH12016501963B1 (es)
SG (1) SG11201608240RA (es)
UA (1) UA118219C2 (es)
WO (1) WO2015150555A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3416945T3 (pl) 2016-02-19 2020-12-28 Sprint Bioscience Ab Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy
PT3416957T (pt) 2016-02-19 2020-09-25 Sprint Bioscience Ab Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
IL302356A (en) 2017-08-23 2023-06-01 Sprint Bioscience Ab Pyridylpyridone compounds
PL3672948T3 (pl) 2017-08-23 2022-12-05 Sprint Bioscience Ab Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
IL302355A (en) 2017-08-23 2023-06-01 Sprint Bioscience Ab Azaindolylpyridone and diazaindolylpyridone compounds
HRP20220497T1 (hr) 2017-08-23 2022-05-27 Sprint Bioscience Ab Spoj morfolinilpiridona
JP2023513854A (ja) * 2020-02-18 2023-04-03 テーセウス ファーマシューティカルズ, インコーポレイテッド 大環状化合物およびその使用
MX2022012558A (es) * 2020-04-07 2023-02-22 iTeos Belgium SA Derivados de diaminas macrocíclicas como inhibidores de ent para el tratamiento de cánceres y combinación de estos con antagonistas del receptor de adenosina.
CN113735879B (zh) * 2020-05-27 2022-05-17 百极弘烨(广东)医药科技有限公司 一种大环jak抑制剂及其应用
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用
CN116113621A (zh) * 2020-07-22 2023-05-12 弗格制药有限公司 氨基酸
WO2023046030A1 (zh) * 2021-09-23 2023-03-30 河南晟翔医药科技有限公司 一种egfr小分子抑制剂、含其的药物组合物及其用途
EP4413003A1 (en) * 2021-10-06 2024-08-14 iTeos Belgium SA Processes for preparing a macrocyclic compound having ent1 inhibiting activity
KR102613509B1 (ko) * 2021-12-15 2023-12-13 환인제약 주식회사 마크로사이클릭 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물
WO2024078263A1 (zh) * 2022-10-09 2024-04-18 药雅科技(上海)有限公司 大环杂环类化合物作为egfr抑制剂的制备及其应用
CN117229300A (zh) * 2023-03-12 2023-12-15 药雅科技(上海)有限公司 Egfr抑制剂的制备及其应用
WO2024094171A1 (zh) * 2022-11-04 2024-05-10 江苏恒瑞医药股份有限公司 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151096B2 (en) * 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
ZA200507806B (en) 2003-03-24 2007-03-28 Actimis Pharmaceuticals Inc 2-phenoxy- and 2-enysulfomamide derivatives with CCR3 antagonistic acitivity for the treatment of asthma and other inflammatory or immunolgical disorders
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
AU2004298448B2 (en) 2003-12-18 2010-09-09 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
EA200601176A1 (ru) 2003-12-18 2006-10-27 Янссен Фармацевтика Н.В. 3-цианохинолиновые производные с антипролиферативной активностью
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
UA92608C2 (en) * 2005-06-30 2010-11-25 Янссен Фармацевтика Н.В. Cyclic anilino - pyridinotriazines as gsk-3 inhibitors
CN101360751B (zh) 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
WO2007059628A1 (en) 2005-11-24 2007-05-31 Oz Communications Inc. Method for securely associating data with http and https sessions
EP2170827B1 (en) 2007-06-21 2013-08-14 Janssen Pharmaceutica, N.V. Indolin-2-ones and aza-indolin-2-ones
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US20090264431A1 (en) 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
WO2009112439A1 (en) * 2008-03-10 2009-09-17 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
BRPI0915105A2 (pt) 2008-06-13 2019-09-24 Novartis Ag composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
CN102458116B (zh) 2009-05-28 2014-12-31 泰特拉洛吉克药业公司 Iap抑制剂
WO2011008788A1 (en) 2009-07-14 2011-01-20 Dawei Zhang Fluoro-substituted compounds as kinase inhibitors and methods of use thereof
TWI513695B (zh) 2009-10-27 2015-12-21 Merck Sharp & Dohme (1,1,1,3,3,3-六氟-2-羥基丙-2-基)苯基衍生物

Also Published As

Publication number Publication date
KR102390276B1 (ko) 2022-04-22
KR20160142316A (ko) 2016-12-12
WO2015150555A1 (en) 2015-10-08
PE20161362A1 (es) 2016-12-17
BR112016021982B1 (pt) 2022-07-26
NZ725399A (en) 2023-01-27
MA39822A (fr) 2018-02-06
CA2942636A1 (en) 2015-10-08
IL248005B (en) 2018-12-31
CA2942636C (en) 2023-03-21
EA201692003A1 (ru) 2017-06-30
US10017509B2 (en) 2018-07-10
UA118219C2 (uk) 2018-12-10
US20170022202A1 (en) 2017-01-26
MX369798B (es) 2019-11-21
EA031246B1 (ru) 2018-12-28
JP2017509687A (ja) 2017-04-06
AU2015239098A1 (en) 2016-09-29
BR112016021982A2 (es) 2017-08-15
MX2016012992A (es) 2016-12-07
CN106164075B (zh) 2021-11-26
AU2015239098B2 (en) 2019-08-01
ES2667723T3 (es) 2018-05-14
PH12016501963A1 (en) 2017-01-09
EP3126364B1 (en) 2018-02-07
CN106164075A (zh) 2016-11-23
PH12016501963B1 (en) 2017-01-09
SG11201608240RA (en) 2016-10-28
JP6529513B2 (ja) 2019-06-12
CN114213415A (zh) 2022-03-22
EP3126364A1 (en) 2017-02-08
MY185491A (en) 2021-05-19

Similar Documents

Publication Publication Date Title
LT3236972T (lt) Antivirusiniai n4-hidroksicitidino dariniai
DK3319956T3 (da) Substituerede oxopyridinderivater
IL265166B (en) Anti-influenza virus pyrimidine derivatives
IL248005B (en) Macrocyclic pyrimidine histories
LT3204359T (lt) Tetrahidroizochinolino dariniai
KR102390274B9 (ko) 마크로사이클릭 피리딘 유도체
EP3319969A4 (en) Diaryl macrocycles-POLYMORPH
DK3189056T3 (da) Cytotoksiske benzodiazepinderivater
LT3457851T (lt) Sobetiromo dariniai
HUE048321T2 (hu) Karabazol származékok
DK3231803T3 (da) Dihydroindolizinonderivat
LT3402792T (lt) Chinolin-2-ono dariniai
EP3564216A4 (en) PYRIMIDINE DERIVATIVE
LT3371168T (lt) Indolin-2-ono dariniai
PT3131898T (pt) Derivados de fluoroalquilfluoreno
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3372589T3 (da) Pyrimidinderivat
PL3137460T3 (pl) Pochodne diheterocyklu połączonego cykloalkilem
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
BR112016026725A2 (pt) Derivados de aminoéster
CL2015000871S1 (es) Pieza de rodillo
FR3025199B1 (fr) Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
IL248900A0 (en) Pyrazine derivatives
GB201416351D0 (en) Heterocyclic derivatives
FR3025200B1 (fr) Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques